Hematology/Oncology Fellow @LSUHS | Former Internal Medicine Residency @LSUHS | Former Internship and Clinical Research Coordinator @StJohns_Blr
Shreveport, LA
Joined December 2010
- Tweets62
- Following162
- Followers98
- Likes274
Rethinking "Variants of Uncertain Significance" in congenital erythrocytosis that are likely pathogenic - read our OA report published on @BMJCaseReports!
#polycythemia #erythrocytosis #VUS
casereports.bmj.com/content/…
Diagnostic stewardship is essential in high-stakes hematology. Reconsidering how we utilize ADAMTS13 testing for aTTP can improve diagnostic accuracy and resource allocation. Read our article published on @AjmQonline
doi.org/10.1097/JMQ.00000000…
Anil Ananthaneni, MD retweeted
Check our viewpoint published @JAMA_current #MedEd
Abstract Factory—Research Culture Harming Medical Education
The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs, diluted conferences. We shouldn't celebrate this—you don't need publications to be a great doctor.
➡️jamanetwork.com/journals/jam…
@utswcancer @rajshekharucms @HiraSMian @ManniMD1 @HemOncFellows @ASCOTECAG
Last day at #ASH25. Excited to share that our work was selected for an Abstract Achievement Award at this year’s ASH meeting in Orlando, FL! @ASH_hematology
Anil Ananthaneni, MD retweeted
Radiation doses of common radiological procedures #4KMedEd 🩻 ☢️
Transatlantic flight: 0.2mSv
Average background radiation: 3mSv/yr
Anil Ananthaneni, MD retweeted
JUST IN: @US_FDA approves imlunestrant (Inluriyo, @EliLillyandCo), an ER antagonist, for adults with ER (+), HER-2 (-), ESR1-mutated metastatic breast cancer with 1+ prior endocrine therapy. Approval based on EMBER-3 published in @NEJM with 1st author @jhaveri_komal @MSKCancerCenter
investor.lilly.com/news-rele…
Anil Ananthaneni, MD retweeted
🚨Have you heard about the latest @US_FDA approval?
✅ #Pembrolizumab has been approved for subcutaneous administration
✅ This may offer greater convenience for patients receiving this drug, including those with #gyncancer like #EndometrialCancer and #CervicalCancer
➡️ More info: fda.gov/drugs/resources-info…
❓ What are your thoughts about this new approval? @leitaomd @karenluMD @LAMcAlarnenMD @JCohenMD @pedroramirezMD @GynCancerMD @amandanfader @BillzamMD @RyanKahnMD1 @GreggNelsonERAS @ShannonWestin @gyncsm #gyncsm #oncology @OncBrothers @PGrivasMDPhD @CParkMD #gcam @KEYTRUDA
Anil Ananthaneni, MD retweeted
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
@FordePatrick et al.
nejm.org/doi/full/10.1056/NE…
Postoperative radiotherapy and survival outcomes in pN2 non-small-cell lung cancer with positive surgical margins: An updated review of the National Cancer Database #ASCO
ascopubs.org/doi/abs/10.1200…
A pleasant surprise in the mail today and honored to be recognized as a top reviewer for JCO Oncology Practice! As an author, I know how much a timely/quality peer review matters. Grateful to contribute to the process! Thank you @ASCO @JCOOP_ASCO
TMA in adult onset Still’s disease is a very rare entity with poor outcomes (>50% permanent complication rate). Unknown if this occurs by chance or association. Please read our report on this topic!
#AOSD #TMA #TTP #Still’s
doi.org/10.1136/bcr-2024-260…
Anil Ananthaneni, MD retweeted
#Weekend_review #TP53 #AML #COMMAND_Consortium
1/ I will share our collaborative effort in looking at different aspects of TP53 mutated AML: 🧵
(1) impact of induction strategy on outcome 10.1002/ajh.26546
(2) Transplant outcome 10.1038/s41375-023-01847-7
(3) Racial disparities in treatment and outcomes 10.1002/cncr.34604
(4) Impact of venetoclax addition to HMA on response and survival 10.1038/s41408-024-01000-2
(5) Impact of “single” vs “multi-hit” TP53 10.3324/haematol.2024.285000
I can not thank enough to all the collaborators of #COMMAND_consortium 🙏🙏🙏
Scheduled partial exchange transfusions were a/w decreased hospital admissions and increased gestational age at delivery in pregnant women with severe sickle cell disease. No significant differences in other natal outcomes including alloimmunization —>
pubmed.ncbi.nlm.nih.gov/3932…
Our results are similar to the TAPS2 RCT feasibility/acceptability study results published recently —> doi.org/10.1182/bloodadvance…
Grateful to the JCO Oncology Practice editorial team and Dr. Burton for the opportunity to discuss the crucial topic of oncofertility. Read our editorial: doi.org/10.1200/OP-24-00457 @JCOOP_ASCO #Oncofertility #CancerCare #FertilityPreservation
Anil Ananthaneni, MD retweeted
Practice-changing news from #GU24: KEYNOTE-564 data support adjuvant pembro as a standard of care after surgery for patients with ccRCC at higher risk for recurrence: brnw.ch/21wGrP1 #ASCODailyNews @DrChoueiri @PBarataMD
Are We Diagnosing and Managing Diabetes in Patients with Sickle Cell Disorders Accurately?
doi.org/10.1182/blood-2023-1…
Immunosuppressant Drug-Associated Non-Hodgkin Lymphoma: A Real-World Pharmacovigilance Database Analysis
doi.org/10.1182/blood-2023-1…
Anil Ananthaneni, MD retweeted
Gear up for #ASH23 by reviewing these abstracts!
🧵 of the 🧵 of #ASH23 abstracts from various notable experts in #MedTwitter! All credit and gratitude to the original writers 🙏
Feel free to add more👇👇
@KarunNeupaneMD @ManniMD1 @msalmanfaisal @AndreaAnampaG @ADesaiMD
Adult‐onset Still's disease with concurrent thrombotic microangiopathy: Observations from pooled analysis for an uncommon finding - European Journal of Haematology - Wiley Online Library onlinelibrary.wiley.com/doi/…
